<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2013-05-12" updated="2020-01-02">
  <drugbank-id primary="true">DB08876</drugbank-id>
  <drugbank-id>DB06667</drugbank-id>
  <name>Taliglucerase alfa</name>
  <description>Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, Î²-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.</description>
  <cas-number>37228-64-1</cas-number>
  <unii>0R4NLX88O4</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7447</ref-id>
        <pubmed-id>21900191</pubmed-id>
        <citation>Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011 Nov 24;118(22):5767-73. doi: 10.1182/blood-2011-07-366955. Epub 2011  Sep 6.</citation>
      </article>
      <article>
        <ref-id>A7448</ref-id>
        <pubmed-id>19277123</pubmed-id>
        <citation>Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E: A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One. 2009;4(3):e4792. doi: 10.1371/journal.pone.0004792. Epub 2009 Mar 11.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D: Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007 Sep;5(5):579-90. Epub 2007 May 24.</synthesis-reference>
  <indication>For the treatment of adult Type 1 Gaucher disease. </indication>
  <pharmacodynamics>Patient's with Type 1 Gaucher disease have a long-term deficiency in the enzyme, glucocerebrosidase. Taliglucerase alfa is a modified form of glucocerebrosidase and is provided to counter this enzyme deficiency, resulting in smaller liver and spleen size, and improved thrombocytopenia and anemia.</pharmacodynamics>
  <mechanism-of-action>Taliglucerase alfa is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals.</mechanism-of-action>
  <toxicity>The most common toxic reaction seen was infusion reactions such as urticaria, arthralgia, headache, and chest pain due to IV administration.</toxicity>
  <metabolism>Metabolism was not determined.</metabolism>
  <absorption>Taliglucerase alfa is administered IV so absorption is 100%.</absorption>
  <half-life>The half life is between 18.9 to 28.7 min.</half-life>
  <protein-binding>Plasma protein binding was not quantified.</protein-binding>
  <route-of-elimination>Route of elimination was not determined.</route-of-elimination>
  <volume-of-distribution>The steady state volume of distribution is between 7.30 to 11.7 L.</volume-of-distribution>
  <clearance>The systemic clearance was approximately 30 L/hr and 20 L/hr for 30 and 60 units/kg, respectively.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Glucosylcerebrosidase</synonym>
    <synonym language="english" coder="">prGC-D</synonym>
    <synonym language="english" coder="">prGCD</synonym>
  </synonyms>
  <products>
    <product>
      <name>Elelyso</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>200 U/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA022458</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Elelyso</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02425637</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>200 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Uplyso</name>
      <company>PFIZER</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Elelyso</name>
      <ingredients>Taliglucerase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Elelyso</name>
      <ingredients>Taliglucerase alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Replacement Therapy</category>
      <mesh-id>D056947</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Gaucher Disease</category>
      <mesh-id>D005776</mesh-id>
    </category>
    <category>
      <category>Glucosidases</category>
      <mesh-id>D005959</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Glucocerebroside-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>200 U/5mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>200 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB11">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08876.pdf?1368417965</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB08876.pdf?1368420168</msds>
  <patents>
    <patent>
      <number>8790641</number>
      <country>United States</country>
      <approved>2014-07-29</approved>
      <expires>2025-10-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8741620</number>
      <country>United States</country>
      <approved>2014-06-03</approved>
      <expires>2024-02-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8227230</number>
      <country>United States</country>
      <approved>2012-07-24</approved>
      <expires>2024-02-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>No food effects found.</food-interaction>
  </food-interactions>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble in water sodium chloride solutions and ethanol.</value>
      <source>From MSDS.</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>56637.9397</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2580H3918N680O727S17</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22330</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910377</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D09675</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Taliglucerase_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1964120</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/elelyso-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/taliglucerase-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004806</id>
      <name>Glucocerebroside</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A17933</ref-id>
            <pubmed-id>22916340</pubmed-id>
            <citation>Haddley K: Taliglucerase alfa for the treatment of Gaucher's disease. Drugs Today (Barc). 2012 Aug;48(8):525-32. doi: 10.1358/dot.2012.48.8.1844808.</citation>
          </article>
          <article>
            <ref-id>A17934</ref-id>
            <pubmed-id>17524049</pubmed-id>
            <citation>Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D: Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007 Sep;5(5):579-90. Epub 2007 May 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>